| SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer Y Xue, B Meehan, Z Fu, XQD Wang, PO Fiset, R Rieker, C Levins, T Kong, ... Nature communications 10 (1), 557, 2019 | 158 | 2019 |
| CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary Y Xue, B Meehan, E Macdonald, S Venneti, XQD Wang, L Witkowski, ... Nature communications 10 (1), 558, 2019 | 118 | 2019 |
| CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers T Kong, R Ahn, K Yang, X Zhu, Z Fu, G Morin, R Bramley, NC Cliffe, Y Xue, ... Cancer research 80 (3), 444-457, 2020 | 117 | 2020 |
| Direct binding between pre-S1 and TRP-like domains in TRPP channels mediates gating and functional regulation by PIP2 W Zheng, R Cai, L Hofmann, V Nesin, Q Hu, W Long, M Fatehi, X Liu, ... Cell reports 22 (6), 1560-1573, 2018 | 47 | 2018 |
| eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer T Kong, Y Xue, R Cencic, X Zhu, A Monast, Z Fu, V Pilon, V Sangwan, ... Molecular cancer therapeutics 18 (11), 2158-2170, 2019 | 43 | 2019 |
| Identification and characterization of hydrophobic gate residues in TRP channels W Zheng, R Hu, R Cai, L Hofmann, Q Hu, M Fatehi, W Long, T Kong, ... The FASEB Journal 32 (2), 639-653, 2018 | 41 | 2018 |
| Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis ST Oh, RA Mesa, CN Harrison, P Bose, AT Gerds, V Gupta, BL Scott, ... Blood Advances 7 (19), 5835-5842, 2023 | 20 | 2023 |
| Ethnic differences in genetic ion channelopathies associated with sudden cardiac death: a systematic review and meta-analysis T Kong, J Feulefack, K Ruether, F Shen, W Zheng, XZ Chen, C Sergi Annals of Clinical & Laboratory Science 47 (4), 481-490, 2017 | 20 | 2017 |
| DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression T Kong, ABA Laranjeira, K Yang, DAC Fisher, LY Yu, ... Nature Cancer 4 (1), 108-127, 2023 | 19 | 2023 |
| Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition T Kong, ABA Laranjeira, TB Collins, ES De Togni, AJ Wong, MC Fulbright, ... Blood advances 6 (2), 611-623, 2022 | 12 | 2022 |
| Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib A Zhou, T Kong, JS Fowles, CL Jung, MJ Allen, DAC Fisher, M Fulbright, ... British journal of haematology, 2022 | 10 | 2022 |
| Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms T Kong, LY Yu, ABA Laranjeira, DAC Fisher, F He, MJ Cox, ST Oh American journal of hematology 98 (7), 1029-1042, 2023 | 8 | 2023 |
| Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer X Zhu, Z Fu, K Dutchak, A Arabzadeh, S Milette, J Steinberger, G Morin, ... Cancer Research 84 (8), 1333-1351, 2024 | 3 | 2024 |
| Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms F He, ABA Laranjeira, T Kong, S Lin, KJ Ashworth, A Liu, NM Lasky, ... The Journal of Clinical Investigation 134 (3), 2024 | 3 | 2024 |
| In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms ABA Laranjeira, T Kong, SC Snyder, MC Fulbright, DAC Fisher, ... Blood, 2024 | 2 | 2024 |
| RSK1 is an exploitable dependency in myeloid malignancies T Kong, A Laranjeira, LY Yu, JS Fowles, DAC Fisher, S Ng, W Yang, F He, ... Blood 142 (Supplement 1), 46-46, 2023 | 1 | 2023 |
| Abstract PR02: RSK1 targeting impedes oncogenic driver and inflammatory cytokine signaling to attenuate myeloid neoplasms T Kong, A Laranjeira, S Oh Blood Cancer Discovery 4 (3_Supplement), PR02-PR02, 2023 | 1 | 2023 |
| Comprehensive profiling of clinical JAK2 inhibitors in myeloproliferative neoplasms T Kong, LY Yu, A Laranjeira, F He, MJ Allen, ST Oh Blood 140 (Supplement 1), 3951-3952, 2022 | 1 | 2022 |
| DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Myeloproliferative Neoplasm Disease Progression T Kong, ABA Laranjeira, K Yang, DAC Fisher, LY Yu, AZ Wang, ... Blood 138, 55, 2021 | 1 | 2021 |
| Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms TB Collins, ABA Laranjeira, T Kong, MC Fulbright, DAC Fisher, ... Experimental Hematology 132, 104178, 2024 | | 2024 |
